Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
出版年份 2023 全文链接
标题
Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
作者
关键词
-
出版物
Clinical and Experimental Nephrology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-02-04
DOI
10.1007/s10157-023-02322-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Relationship between serum lipid concentrations and impaired renal function in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry Study
- (2021) Toshiaki Nakano et al. Clinical and Experimental Nephrology
- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
- (2019) Archna Bajaj et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Lipotoxicity in Kidney, Heart, and Skeletal Muscle Dysfunction
- (2019) Hiroshi Nishi et al. Nutrients
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study
- (2018) Anna Masajtis-Zagajewska et al. RENAL FAILURE
- Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
- (2017) Toshinobu Maki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy
- (2014) Akiko Takazakura et al. Journal of Diabetes Investigation
- Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus
- (2013) Frank M. Sacks et al. CIRCULATION
- Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis
- (2011) Tetsuo Shoji et al. Journal of Atherosclerosis and Thrombosis
- Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
- (2008) Giovanni F M Strippoli et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started